Valneva's Covid vaccine gets UK approval

BRITAIN has approved a new coronavirus vaccine by the Austrian-French drugmaker Valneva, the UK regulatory authority MHRA said on Thursday (14).

"An approval has been granted after the Valneva Covid-19 vaccine was found to meet the required safety, quality and effectiveness standards," the Medicines and Healthcare products Regulatory Agency said in a statement.

Last month, Valneva's Covid-19 vaccine -- which uses the traditional technology of inactivated virus -- received its first approval with an emergency authorisation for use in Bahrain.

Valneva had committed to supplying the Gulf kingdom with one million doses in an advance purchase agreement last year.

Valneva CEO Thomas Lingelbach delivers a speech following a visit from Scotland's First Minister Nicola Sturgeon to the new Valvena Scotland vaccine manufacturing plant on March 28, 2022 in Livingston, Scotland. (Photo by Andy Buchanan - Pool/Getty Images)

The Austrian-French firm had also signed an agreement with the EU Commission over the supply of up to 60 million doses in 2022 and 2023.

Valneva is the sixth coronavirus vaccine to be approved in the UK, after AstraZeneca, Pfizer, Moderna, Janssen (Johnson & Johnson), and Novavax.

"The independent Commission on Human Medicines and its Covid-19 Expert Working Group has carefully considered the available evidence (and) the benefit risk balance is positive," the commission's president, Munir Pirmohamed, said in the statement.

The vaccine is approved for use in people aged 18-50 with the two doses to be taken at an interval of at least 28 days.

The vaccine can be stored at fridge temperature, meaning it can be used in countries where storage at very low temperatures is not available.

Britain was one of the countries hardest hit by the global coronavirus pandemic, where it killed more than 171,000 people.

More than 92 per cent of the population aged 12 or over has had a vaccine dose, 86 per cent a second dose and 68 per cent a booster.

This week, Britain decided to expand access to Pfizer's oral antiviral Covid-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population.

Paxlovid, a combination of Pfizer's new pill with an older antiviral ritonavir, was made available to thousands of people with compromised immune systems in Britain in February.

(Agencies)